Skip to main content
Zydus Wellness Limited logo

Zydus Wellness Limited — Investor Relations & Filings

Ticker · ZYDUSWELL ISIN · INE768C01028 LEI · 335800YCS4FG8P1D1Y21 BSE.NS Manufacturing
Open in API
Filings indexed 900 across all filing types
Latest filing 2026-03-03 Regulatory Filings
Country IN India
Listing BSE.NS ZYDUSWELL

About Zydus Wellness Limited

https://www.zyduswellness.com/

Zydus Wellness Limited is a consumer wellness organization dedicated to providing products that support a healthy lifestyle. The company manages a portfolio of established brands across several categories, including nutritional supplements, energy drinks, sweeteners, skincare, and healthy spreads. Its core product lineup features Sugar Free, a leading brand in the sugar substitute market; Glucon-D, a prominent glucose-based energy drink; and Complan, a fortified health food drink. Additionally, the portfolio includes Nycil prickly heat powder, Everyuth skincare products, and Nutralite table spreads. The company focuses on product innovation and quality to meet the demands of health-conscious consumers. Through a combination of research-driven development and a comprehensive distribution infrastructure, the entity provides functional wellness solutions designed to enhance the daily lives of its target audience.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 100% confidence The document is a disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015, specifically a Form B filing reporting a change in shareholding by a designated person (Chief Financial Officer) of Zydus Wellness Limited. It details the acquisition of shares from the open market by an insider. The document is a regulatory compliance filing related to insider trading disclosures, not a financial report, earnings release, or management announcement. It is not a report publication announcement or a certification letter but a formal regulatory disclosure. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement but a formal regulatory filing.
2026-03-03 English
Updates
Regulatory Filings Classification · 100% confidence The document is a disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015, specifically a Form B filing reporting acquisition of shares by a designated person of the company. It details insider trading activity, including shareholding before and after acquisition, dates, and mode of acquisition. There is no financial report, earnings data, or management discussion. The document is a regulatory compliance filing related to insider trading disclosures, which fits the category of Regulatory Filings (RNS). The document length is 4052 characters, which is short and focused on a specific regulatory disclosure, not a full report or announcement of a report publication.
2026-03-02 English
Updates
Director's Dealing Classification · 95% confidence The document is a mandatory continuous disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015, showing the acquisition of shares by a designated person (CFO) of Zydus Wellness Limited. This is a classic insider trading disclosure by a company director/executive. Hence it falls under Director's Dealing (DIRS).
2026-02-17 English
General Updates
Director's Dealing Classification · 98% confidence The document is a SEBI Form B disclosure under the PIT Regulations showing a company director’s acquisition of shares (insider trading disclosure). This exactly matches the Director’s Dealing category (reports of personal share transactions by directors/executives).
2026-02-16 English
Updates
Director's Dealing Classification · 95% confidence The document is a disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015, specifically a Form B filing reporting acquisition of shares by a designated person or their immediate relative. It includes detailed information about the securities acquired, dates, mode of acquisition, and exchanges involved. There is no indication of financial results, management discussion, or other report types. The document is a regulatory disclosure about insider trading activity, which fits the definition of Director's Dealing (DIRS) filings, as it reports personal share transactions by company directors or designated persons. The document length is about 14,404 characters, sufficient for a detailed disclosure. Therefore, the correct classification is DIRS with high confidence.
2026-02-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an earnings conference call held on February 3, 2026, for Zydus Wellness Limited's Q3 FY2026 results. It includes detailed management commentary on financial performance, business updates, and a Q&A session with analysts. The text explicitly mentions it is a transcript of the earnings call, which is a full text record of the call including management remarks and Q&A. This matches the definition of a Call Transcript (CT). The document is lengthy (15,000 characters) and contains substantive financial discussion, not just an announcement or summary. Therefore, the correct classification is CT with high confidence.
2026-02-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.